Therapeutic advances in 2020 compared with the previous 9 years |
![](/Docu/Images/PlaquettesAnneeMedic2020.jpg) |
|
![Progrès notable](/Docu/Images/ComprimeBleu.png) |
Notable advance |
![Pas de progrès](/Docu/Images/ComprimeJaune.png) |
No proven advantages
|
|
![Progrès minime](/Docu/Images/ComprimeBleuCiel.png) |
Minimal advance |
![Pas de progrès](/Docu/Images/ComprimeRouge.png) |
More dangerous than useful |
|
|
|
Prescrire’s ratings of new products and indications over the past 10 years |
|
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
![Bravo](/Docu/Images/CotationsPI/BravoPI.jpg) |
BRAVO |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
0 |
1 |
![A Real Advance](/Docu/Images/CotationsPI/RealAdvancePI.jpg) |
A REAL ADVANCE
|
0 |
1 |
0 |
2 |
3 |
1 |
1 |
2
|
1 |
2 |
![Offers an advantage](/Docu/Images/CotationsPI/OffersAdvantagePI.jpg) |
OFFERS AN ADVANTAGE
|
3 |
3 |
6 |
5 |
5 |
5 |
9 |
11
|
10 |
6 |
![Possibly helpful](/Docu/Images/CotationsPI/PossiblyHelpfulPI.jpg) |
POSSIBLY HELPFUL
|
13 |
14 |
12 |
15 |
15 |
9 |
18 |
22 |
13 |
18 |
![Nothing new](/Docu/Images/CotationsPI/NothingNewPI.jpg) |
NOTHING NEW
|
53 |
42 |
48 |
35 |
43 |
56 |
45 |
50 |
61 |
55 |
![Judgement reserved](/Docu/Images/CotationsPI/JudgementReservedPI.jpg) |
JUDGEMENT RESERVED
|
7 |
7 |
9 |
10 |
6 |
5 |
4 |
5
|
9 |
17 |
![Not acceptable](/Docu/Images/CotationsPI/NotAcceptablePI.jpg) |
NOT ACCEPTABLE
|
16 |
15 |
15 |
19 |
15 |
16 |
15 |
9
|
14 |
10 |
TOTAL |
92 |
82 |
90 |
87 |
87 |
92 |
92 |
99 |
108 |
109 |
Every month, Prescrire publishes independent, comparative, systematic reviews of the latest developments in the pharmaceutical market, be they new active substances, new combinations, new dose strengths, new pharmaceutical forms or new indications. We also closely monitor news of drugs' adverse effects, market withdrawals (instigated by pharmaceutical companies or regulatory authorities), shortages, and the regulatory environment for health products, particularly at EU level.
Our aim is to help subscribers distinguish between true advances in health care and new products or uses that are no better than existing treatments or should never have been authorised, due to uncertainty over their harms or benefits or because they are clearly dangerous.
©Prescrire 1 April 2021
Source: "Drugs in 2020: a brief review" Prescrire International 2021; 30 (225): 108-109. Free.
Enjoy full access to Prescrire International, and support independent information
|